haktutsfordailyspin| Health Yuan subsidiary only obtained the registration certificate of fluticasone propionate inhalation: treatment of acute asthma attacks aged 4-16

News summary

Shanghai Fangyu, a subsidiary of Health Yuan, set a record and approved fluticasone propionate aerosol suspension for inhalationhaktutsfordailyspin, targeting asthma patients aged 4-16, may significantly enhance the company's market competitiveness.

Newsletter text

[Shanghai Fangyu Drug Registration Certificate has been approved, focusing on the treatment of asthma in children and adolescents]

On May 27, Health Yuan (600380) announced that its holding subsidiary Shanghai Fangyu successfully obtained a drug registration certificate.

The drug, called fluticasone propionate aerosol suspension for inhalation, will help children and adolescents aged 4-16 to provide treatment solutions for acute attacks of mild to moderate asthma.